NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What is a risk of using erythropoiesis-stimulating agents (ESAs) when hemoglobin levels exceed 11 g/dL?

Decreased risk of infections
Increased risk of death
Reduced need for blood transfusions
Lower risk of hypertension

The correct answer is: Increased risk of death

Exceeding a hemoglobin level of 11 g/dL with the use of erythropoiesis-stimulating agents (ESAs) poses a higher risk of death. This is because increasing the production of red blood cells beyond the body's natural capacity can lead to thickened blood and increased risk of blood clots, stroke, and heart attack. The other options listed are incorrect because ESAs have not been found to have any impact on reducing infection risk, reducing the need for blood transfusions or lowering the risk of hypertension. It is important to carefully monitor and adjust ESA use to avoid potential risks.